Insider filing · KALV

Venrock Healthcare Capital Partners III, L.P. bought $929K of KalVista Pharmaceuticals (KALV)

Executed Feb 7 2025, disclosed Feb 11 2025, 4 days later.

Not yet measured: the 21-session window has not closed, or the prices around it are not on record.

VP Venrock Healthcare Capital Partners III, L.P. 10% owner profile →

Venrock Healthcare Capital Partners III, L.P. (10% owner) filed 3 Form 4 reports as a reporting entity in the trailing twelve months (3 purchases, 0 sales), most often in Lycia Therapeutics, Inc. (LYCA). The largest single filing was $37.7M of LYCA (2,045,440 sh across 6 lots, as filed), executed Oct 23. The median gap between execution and disclosure was 2 days.

KALV KALV KALV · 19 filings in 24 months ticker → Insider filings, newest first→ View the original filing at www.sec.gov→